Elo Mutual Pension Insurance Co Acquires 110,685 Shares of Pfizer Inc. $PFE

Elo Mutual Pension Insurance Co grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 19.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 676,539 shares of the biopharmaceutical company’s stock after buying an additional 110,685 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Pfizer were worth $17,238,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the third quarter valued at about $29,000. Howard Hughes Medical Institute bought a new stake in Pfizer during the second quarter worth about $30,000. True Wealth Design LLC grew its stake in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. Darwin Wealth Management LLC bought a new position in shares of Pfizer during the second quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in Pfizer during the 2nd quarter valued at about $33,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Pfizer Stock Performance

Shares of PFE stock opened at $27.61 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The firm has a market capitalization of $156.98 billion, a price-to-earnings ratio of 20.30 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a 50 day moving average price of $26.13 and a 200 day moving average price of $25.41.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price for the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $27.70.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.